Anidulafungin has not been studied in patients with Candida endocarditis, osteomyelitis or meningitis.The efficacy of anidulafungin has only been evaluated in a limited number of neutropenic patients (see Pharmacology: Pharmacodynamics under Actions).
Anaphylactic Reactions: Anaphylactic reactions, including shock, were reported with the use of anidulafungin. If these reactions occur, anidulafungin should be discontinued and appropriate treatment administered. (See Adverse Reactions).
Infusion-Related Reactions: Infusion-related adverse events have been reported with anidulafungin, including rash, urticaria, flushing, pruritus, dyspnea, bronchospasm and hypotension. Infusion-related adverse events are infrequent when the rate of anidulafungin infusion does not exceed 1.1 mg/minute (see Dosage & Administration, Adverse Reactions and Cautions for Usage).
Hepatic Effects: Laboratory abnormalities in liver function tests have been seen in healthy subjects and patients treated with anidulafungin. In some patients with serious underlying medical conditions who were receiving multiple concomitant medications along with anidulafungin, clinically significant hepatic abnormalities have occurred. Isolated cases of significant hepatic dysfunction, hepatitis, or hepatic failure have been reported in patients; a causal relationship to anidulafungin has not been established. Patients who develop abnormal liver function tests during anidulafungin therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing anidulafungin therapy.
Effects on ability to drive and use machines: No studies on the effects on the ability to drive and use machines have been performed.